2 news items
Poseida Therapeutics Presents New Phase 1 Data At AACR 2024 Supporting Potential Of P-BCMA-ALLO1 Allogeneic CAR-T Therapy To Benefit Broad Range Of Patients With Multiple Myeloma
PSTX
8 Apr 24
trial with the goal of delivering the same benefits in solid tumors as we have seen in myeloma. We look forward to sharing more fulsome datasets on both our BCMA and MUC1-C programs in the second half of 2024."
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
PSTX
8 Apr 24
and are directly applying these learnings to our P-MUC1C-ALLO1 trial with the goal of delivering the same benefits in solid tumors as we have seen
- Prev
- 1
- Next